Syndax Pharmaceuticals, Inc. (SNDX)
NASDAQ: SNDX · Real-Time Price · USD
12.18
-1.00 (-7.59%)
Mar 31, 2025, 1:13 PM EDT - Market open
Syndax Pharmaceuticals Revenue
In the year 2024, Syndax Pharmaceuticals had annual revenue of $23.68M. Syndax Pharmaceuticals had revenue of $7.68M in the quarter ending December 31, 2024.
Revenue (ttm)
$23.68M
Revenue Growth
n/a
P/S Ratio
47.66
Revenue / Employee
$87,704
Employees
270
Market Cap
1.05B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
SNDX News
- 25 days ago - Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Syndax Pharmaceuticals, Inc. (SNDX) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Syndax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 4 weeks ago - Syndax Announces Participation in March Investor Conferences - GlobeNewsWire
- 5 weeks ago - Syndax to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call and Webcast on March 3, 2025 - GlobeNewsWire
- 6 weeks ago - Kuehn Law Encourages Investors of Syndax Pharmaceuticals, Inc. to Contact Law Firm - GlobeNewsWire
- 2 months ago - Syndax Announces Participation in February Investor Conferences - PRNewsWire
- 2 months ago - Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo™ (axatilimab-csfr) 9 mg and 22 mg Vial Sizes - PRNewsWire